Gero Hütter

Dr. Gero Hütter


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2011 in Clinical and Experimental Immunology
Verified
Journal Article
Closed access
PDF file
GHGero Hütter
Gero Hütter
JZJ A Zaia
J A Zaia

1 January 2011 in The Scientific World Journal
Verified
Journal Article
Open access
PDF file
GHGero Hütter
Gero Hütter
SGSusanne Ganepola
Susanne Ganepola
Today, 30 years after the onset of the HIV pandemic, although treatment strategies have considerably improved, there is still no cure for the disease. Recently, we described a successful hematopoietic stem cell transplantation in an HIV-1–infected patient, transferring donor-derived cells with a natural resistance against HIV infection. These hematopoietic stem cells engrafted, proliferated, and differentiated into mature myeloid and lymphoid cells. To date, the patient has not required any antiretroviral treatment, more than 4 years after allogeneic transplantation. In the analysis of peripheral blood cells and different tissue samples, including gut, liver, and brain, no viral load or proviral DNA could be detected. Our report raises the hope for further targeted treatment strategies against HIV and represents a successful personalized treatment with allogeneic stem cells carrying a beneficial gene. However, this case has ignited a controversy regarding the question of whether this patient has achieved complete eradication of HIV or not. Here we give an update on open questions, unsolved aspects, and clinical consequences concerning this unique case.

1 January 2011 in Journal of Inflammation
Verified
Journal Article
Open access
PDF file
GHGero Hütter
Gero Hütter
MNMartin Neumann
Martin Neumann
DNDaniel Nowak
Daniel Nowak
SKStefan Klein
Stefan Klein
HKHarald Klüter
Harald Klüter
WHWolf-K Hofmann
Wolf-K Hofmann
The natural function of the C-C chemokine receptor type 5 (CCR5) is poorly understood. A 32 base pair deletion in the CCR5 gene (CCR5-delta32) located on chromosome 3 results in a non-functional protein. It is supposed that this deletion causes an alteration in T-cell response to inflammation. For example, the presence of the CCR5-delta32 allele in recipients of allografts constitutes as an independent and protective factor associated with a decreased risk of graft-versus-host disease (GVHD) and graft rejection. However, the mechanism of this beneficial effect of the deletion regarding GVHD is unknown. In this survey we searched for a CCR5-delta32 associated regulation of critical genes involved in the immune response and the development of GVHD.

30 December 2013 in Viruses
Verified
Journal Article
Open access
PDF file
BBBryan P. Burke
Bryan P. Burke
MBMaureen P. Boyd
Maureen P. Boyd
HIHelen Impey
Helen Impey
LBLouis R. Breton
Louis R. Breton
JBJeffrey S. Bartlett
Jeffrey S. Bartlett
GHGero Hütter
Gero Hütter
Human immunodeficiency virus type 1 (HIV-1) infection of target cells requires CD4 and a co-receptor, predominantly the chemokine receptor CCR5. CCR5-delta32 homozygosity results in a truncated protein providing natural protection against HIV infection—this without detrimental effects to the host—and transplantation of CCR5-delta32 stem cells in a patient with HIV (“Berlin patient”) achieved viral eradication. As a more feasible approach gene-modification strategies are being developed to engineer cellular resistance to HIV using autologous cells. We have developed a dual therapeutic anti-HIV lentiviral vector (LVsh5/C46) that down-regulates CCR5 and inhibits HIV-1 fusion via cell surface expression of the gp41-derived peptide, C46. This construct, effective against multiple strains of both R5- and X4-tropic HIV-1, is being tested in Phase I/II trials by engineering HIV-resistant hematopoietic cells.

1 May 2011 in Leukemia Research
Verified
Journal Article
Closed access
GHGero Hütter
Gero Hütter
MKMartin Kaiser
Martin Kaiser
MNMartin Neumann
Martin Neumann
MMMartin Mössner
Martin Mössner
DNDaniel Nowak
Daniel Nowak
WHWolf-Karsten Hofmann
Wolf-Karsten Hofmann

1 January 2013 in AIDS Research and Therapy
Verified
Journal Article
Open access
PDF file
GHGero Hütter
Gero Hütter
CBChristian Blüthgen
Christian Blüthgen
MNMartin Neumann
Martin Neumann
MRMark Reinwald
Mark Reinwald
DNDaniel Nowak
Daniel Nowak
HKHarald Klüter
Harald Klüter
CCR5-delta32 heterozygous individuals are susceptible to HIV-1. However, it is not clear if there is a relevant protective effect against transmission and a beneficial effect in terms of HIV progression which cannot be attributed to CCR5 surface density alone. Therefore we investigated HIV-1 dependency factors (HDF) which might be differently regulated in CCR5 wild type (WT) and CCR5-delta32 heterozygous individuals.